Scholarlink

<p>The Asian Working Group for Sarcopenia (AWGS) presents an updated 2025 consensus reframing sarcopenia management through a life-course approach to muscle health promotion. While aligning with the Global Leadership Initiative in Sarcopenia (GLIS), this update provides healthcare providers with Asia-specific guidance. The consensus introduces three key refinements: first, expanding sarcopenia diagnosis to middle-aged adults (50‒64 years) with validated diagnostic thresholds; second, simplifying the diagnostic algorithm to require only concurrent low muscle mass and strength, with physical performance as an outcome measure; and third, introducing an enhanced muscle health framework recognizing skeletal muscle as vital for healthy longevity, emphasizing cross-talk with brain, bone, adipose tissue and immune systems. This framework leverages the World Health Organization’s Integrated Care for Older People (ICOPE) implementation for enhanced case-finding through natural overlap between muscle health and ICOPE’s intrinsic capacity domains. The consensus provides evidence-based recommendations for multimodal interventions that combine resistance exercise with nutritional supplementation, representing advancement toward proactive muscle health promotion and establishing a framework for reducing age-related decline in Asian populations.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

A focus shift from sarcopenia to muscle health in the Asian Working Group for Sarcopenia 2025 Consensus Update

  • 期刊论文

  • 发表日期：

    2025年11月4日

查看全文
  • Liang-Kung Chen,
  • Fei-Yuan Hsiao,
  • Masahiro Akishita,
  • Prasert Assantachai,
  • Wei-Ju Lee,
  • Wee Shiong Lim,
  • Weerasak Muangpaisan,
  • Miji Kim,
  • Reshma Aziz Merchant,
  • Li-Ning Peng,
  • Maw Pin Tan,
  • Chang Won Won,
  • Minoru Yamada,
  • Jean Woo,
  • Hidenori Arai

摘要

The Asian Working Group for Sarcopenia (AWGS) presents an updated 2025 consensus reframing sarcopenia management through a life-course approach to muscle health promotion. While aligning with the Global Leadership Initiative in Sarcopenia (GLIS), this update provides healthcare providers with Asia-specific guidance. The consensus introduces three key refinements: first, expanding sarcopenia diagnosis to middle-aged adults (50‒64 years) with validated diagnostic thresholds; second, simplifying the diagnostic algorithm to require only concurrent low muscle mass and strength, with physical performance as an outcome measure; and third, introducing an enhanced muscle health framework recognizing skeletal muscle as vital for healthy longevity, emphasizing cross-talk with brain, bone, adipose tissue and immune systems. This framework leverages the World Health Organization’s Integrated Care for Older People (ICOPE) implementation for enhanced case-finding through natural overlap between muscle health and ICOPE’s intrinsic capacity domains. The consensus provides evidence-based recommendations for multimodal interventions that combine resistance exercise with nutritional supplementation, representing advancement toward proactive muscle health promotion and establishing a framework for reducing age-related decline in Asian populations.